Protelight Pharmaceuticals

Jiangyin, China · Founded 2009 · In IPO Registration

Developer and manufacturer of novel antimicrobial peptide drugs and therapeutic candidates designed for drug-resistant infections, metabolic disorders, and autoimmune diseases. Protelight Pharmaceuticals is based in Jiangyin, China and was founded in 2009. Its last reported valuation was $352 million in Nov 2025. It has raised $115 million.

Last reported valuation
$351.9M
Oct 2026
Priced at
—
Total raised
$115.0M
Last round
—

Protelight Pharmaceuticals key facts

as of Oct 2026
  • Developer and manufacturer of novel antimicrobial peptide drugs and therapeutic candidates designed for drug-resistant infections, metabolic disorders, and autoimmune diseases.
  • Protelight Pharmaceuticals is valued at approximately $351.9M as of Oct 2026 (last reported valuation).
  • It has raised $115.0M; the latest was IPO in Feb 2026.
  • Notable investors include Shenzhen Yifeng Investment Management Enterprise, Infinity Group, Wuxi Guolian Development (Group), Cherami Investment Group, Qingdao Conson Financial Holdings — 12 tracked in total.
  • Status: In IPO Registration.
Last reported valuation
LOW confidence
$351.9M

Protelight Pharmaceuticals's last reported valuation, Nov 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Protelight Pharmaceuticals with a free account
  • ·The complete investor list: 12 names
  • ·Watch Protelight Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Protelight Pharmaceuticals funding rounds

No rounds on record

No funding rounds for Protelight Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Protelight Pharmaceuticals valuation

Protelight Pharmaceuticals's last reported valuation was $352 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.

Protelight Pharmaceuticals investors

12 investors are on record for Protelight Pharmaceuticals, including Shenzhen Yifeng Investment Management Enterprise, Infinity Group, Wuxi Guolian Development (Group) and Cherami Investment Group.

About Protelight Pharmaceuticals

Developer and manufacturer of novel antimicrobial peptide drugs and therapeutic candidates designed for drug-resistant infections, metabolic disorders, and autoimmune diseases. The company provides innovative peptide therapies and proprietary technology platforms, enabling patients and healthcare providers with new treatment mechanisms, improved efficacy, and solutions for unmet clinical needs.

Sector
Healthcare
HQ
Jiangyin, China
Founded
2009
Employees
109
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.